The OARD1 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for functional studies of OARD1 (TARG1) in a B-lymphocyte background. This gene-disrupted pool is generated by CRISPR/Cas9-mediated target-gene disruption in the Raji cell line, producing a heterogeneous population of cells with loss-of-function mutations. The polyclonal format avoids clonal selection artifacts and provides a robust model for studying OARD1-dependent pathways in a cancer-relevant cellular context.
The parental Raji cell line is derived from a Burkitt’s lymphoma patient and is Epstein-Barr virus (EBV)-positive. Raji cells exhibit characteristic B-cell markers and are widely employed as a model for B-cell malignancies, immune signaling studies, and lymphomagenesis. Their rapid proliferation and well-characterized genetic background make them suitable for high-throughput screening and mechanistic investigations.
OARD1 is a mono-ADP-ribosylhydrolase that removes the terminal ADP-ribose from mono-ADP-ribosylated proteins, reversing PARP-mediated modification. It acts downstream of PARP1 and cellular stress, targeting ADP-ribosylated histones, DNA repair proteins like XRCC1, and transcription factors. OARD1 interacts with ADP-ribosylated substrates and cooperates with PARP1 and PARG to regulate ADP-ribosylation dynamics, thereby modulating DNA repair, transcription, and protein stability.
In Raji B-lymphoma cells, disruption of OARD1 perturbs the balance of mono-ADP-ribosylation, potentially impairing DNA damage response and altering gene expression programs. Given the role of PARP signaling in maintaining genomic integrity and the sensitivity of B-cell lymphomas to PARP inhibitors, the OARD1-knockout model provides a unique tool to dissect ADP-ribosylation-dependent survival mechanisms. The loss of OARD1 may confer altered sensitivity to genotoxic agents or PARP inhibition, offering insights into therapeutic vulnerabilities in lymphoma.
Applications include western blot analysis of global ADP-ribosylation levels, ??H2AX immunofluorescence to quantify DNA damage, PARP activity assays, and comet assays for DNA strand break detection. Transcriptomic profiling via RNA-seq can elucidate OARD1-dependent gene expression changes, while cell viability assays with DNA-damaging agents enable screening for chemo- or PARP-inhibitor sensitivity. The model is particularly relevant for studying ADP-ribosylation signaling in B-cell lymphoma, investigating DNA repair defects in cancer, and modeling aspects of TARG1-associated neurodegeneration. For further details, please contact Ascent Research.
